US Stocks
US Options
Emerging Asia
GBP Cash Savings
Charts & Tools
Paper Trading
Extended Hours
Overview
Desktop
Wall Street JournalC
CANF
Can Fite Biophar
2.70
-0.05-1.82%Closed17:31 10/17 EDT
OPEN/PREV CLOSE2.700/2.700
TODAY RANGE2.480-2.800
VOL78.33K
MARKET CAP16.46M
52 WEEK RANGE1.810-4.690
AVG VOL (3M)114.24K
% TURNOVER1.28%
TURNOVER0
P/E (TTM)-1.9052
% RANGE11.11%
EPS(TTM)-1.4172
P/E(FORWARD)-1.9471
P/B6.07
BVPS0.4449
DIVIDEND--
P/S5,400.00
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP16.46M
SHARES OUTSTANDING6.10M
NEXT EARNINGS11/28-12/02
FREE FLOAT6.10M
LOT SIZE1
EX-DIV DATE01/09/2023
News
Press Releases
Financial Reports
Profile
Dow Jones·10/10 12:23
Can-Fite Biopharma Is Maintained at Buy by EF Hutton
Dow Jones·10/10 12:23
Can-Fite Biopharma Price Target Maintained With a $10.00/Share by EF Hutton
Benzinga·10/10 12:14
EF Hutton Maintains Buy on Can Fite Biofarma, Maintains $10 Price Target
Seeking Alpha·10/09 19:22
Can-Fite stock rallies 17% on FDA orphan drug designation
TipRanks·10/09 11:27
Can-Fite’s Namodenoson Gains FDA Orphan Status
TipRanks·10/09 11:05
Can-Fite BioPharma announces FDA granted ODD for Namodenoson
TipRanks·10/08 10:10
Can-Fite BioPharma treatment of pancreatic cancer granted FDA orphan status
Dow Jones·09/24 14:36
Can-Fite Biopharma Is Maintained at Buy by EF Hutton
Dow Jones·09/24 14:36
Can-Fite Biopharma Price Target Maintained With a $10.00/Share by EF Hutton
Benzinga·09/24 14:27
EF Hutton Maintains Buy on Can Fite Biofarma, Maintains $10 Price Target
Seeking Alpha·09/24 11:49
Can-Fite gains after agreement for animal arthritis drug
TipRanks·09/24 11:27
Can-Fite BioPharma’s Lucrative Veterinary Licensing Deal
TipRanks·09/16 11:27
Can-Fite Advances Pancreatic Cancer Drug Trial
Same Industry
Name/Symbol
Change%
Price